Cargando…

The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment

INTRODUCTION: Inversion of the CD4:CD8 ratio (<1) has been identified as a hallmark of immunosenescence and an independent predictor of mortality in the general population. We aimed to assess the association between the CD4:CD8 ratio and intima-media thickness (IMT) progression in treated HIV-inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernal, Enrique, Serrano, Jose, Perez, Ana, Valero, Salvador, Garcia, Eva, Marín, Irene, Muñoz, Angeles, Miguel Gomez Verdú, Jose, Vera, Carmen, Cano, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225384/
https://www.ncbi.nlm.nih.gov/pubmed/25397469
http://dx.doi.org/10.7448/IAS.17.4.19723
_version_ 1782343494597083136
author Bernal, Enrique
Serrano, Jose
Perez, Ana
Valero, Salvador
Garcia, Eva
Marín, Irene
Muñoz, Angeles
Miguel Gomez Verdú, Jose
Vera, Carmen
Cano, Alfredo
author_facet Bernal, Enrique
Serrano, Jose
Perez, Ana
Valero, Salvador
Garcia, Eva
Marín, Irene
Muñoz, Angeles
Miguel Gomez Verdú, Jose
Vera, Carmen
Cano, Alfredo
author_sort Bernal, Enrique
collection PubMed
description INTRODUCTION: Inversion of the CD4:CD8 ratio (<1) has been identified as a hallmark of immunosenescence and an independent predictor of mortality in the general population. We aimed to assess the association between the CD4:CD8 ratio and intima-media thickness (IMT) progression in treated HIV-infected patients as a marker of early atherosclerosis. MATERIALS AND METHODS: A longitudinal study during three years was conducted in 120 HIV-infected patients receiving antiretroviral treatment (ART). We analyzed the associations between the CD4:CD8 ratio, cardiovascular risk factor and antiretroviral (ARV) treatment and progression of subclinical atherosclerosis assessed using carotid IMT at baseline and after three years. RESULTS: Finally, 96 patients completed the study. Seventy-six (79.1%) patients were male, aged 44±10 years, 39 (40.6%) were on treatment with Protease inhibitors, 49 (51.04%) with non-nucleoside reverse transcriptase inhibitors (NNRTI), 6 (6.25%) with integrase inhibitors, 3 (3.12%) with maraviroc and 2 (2.08%) only with nucleoside reverse transcriptase inhibitors (NRTI). The mean of ARV exposition was 6.9±5.9 years. Twenty six (27 %) patients had family history of ischemic heart disease, 51 (53.12%) were smokers, 12 (12.5%) hypertensive, 4 (4.16%) type 2 diabetes, 23 (23.9%) with dyslipidemia and 31 (32.3%) were infected with C hepatitis virus. Baseline IMT was significantly associated with age (rho=0.497; p<0.001), basal glucemia (rho=0.323; p=0.001), triglycerides (rho=0.232; p=0.023), Framingham score (rho=0.324; p=0.001), CD4:CD8 ratio (rho=−0.176; p=0.05) and dyslipidemia (0.72±0.16 mm vs 0.63±0.11 mm; p=0.029). In multivariable analysis where cardiovascular risk factor and ARV were included, IMT progression was inversely associated with CD4:CD8 ratio (OR=0.283; CI 95% 0.099–0.809; p=0.019) and treatment with NNRTI (OR=0.283; CI 95% 0.099–0.809; p=0.019). CONCLUSIONS: The inversion of CD4:CD8 ratio in treated HIV-infected patients is independently associated with IMT progression, a marker of age-associated disease. Therefore, it might be clinically useful as predictor of cardiovascular events. Surprisingly, there was a positive correlation between receiving NNRTI and progression of IMT.
format Online
Article
Text
id pubmed-4225384
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-42253842014-11-13 The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment Bernal, Enrique Serrano, Jose Perez, Ana Valero, Salvador Garcia, Eva Marín, Irene Muñoz, Angeles Miguel Gomez Verdú, Jose Vera, Carmen Cano, Alfredo J Int AIDS Soc Poster Sessions – Abstract P191 INTRODUCTION: Inversion of the CD4:CD8 ratio (<1) has been identified as a hallmark of immunosenescence and an independent predictor of mortality in the general population. We aimed to assess the association between the CD4:CD8 ratio and intima-media thickness (IMT) progression in treated HIV-infected patients as a marker of early atherosclerosis. MATERIALS AND METHODS: A longitudinal study during three years was conducted in 120 HIV-infected patients receiving antiretroviral treatment (ART). We analyzed the associations between the CD4:CD8 ratio, cardiovascular risk factor and antiretroviral (ARV) treatment and progression of subclinical atherosclerosis assessed using carotid IMT at baseline and after three years. RESULTS: Finally, 96 patients completed the study. Seventy-six (79.1%) patients were male, aged 44±10 years, 39 (40.6%) were on treatment with Protease inhibitors, 49 (51.04%) with non-nucleoside reverse transcriptase inhibitors (NNRTI), 6 (6.25%) with integrase inhibitors, 3 (3.12%) with maraviroc and 2 (2.08%) only with nucleoside reverse transcriptase inhibitors (NRTI). The mean of ARV exposition was 6.9±5.9 years. Twenty six (27 %) patients had family history of ischemic heart disease, 51 (53.12%) were smokers, 12 (12.5%) hypertensive, 4 (4.16%) type 2 diabetes, 23 (23.9%) with dyslipidemia and 31 (32.3%) were infected with C hepatitis virus. Baseline IMT was significantly associated with age (rho=0.497; p<0.001), basal glucemia (rho=0.323; p=0.001), triglycerides (rho=0.232; p=0.023), Framingham score (rho=0.324; p=0.001), CD4:CD8 ratio (rho=−0.176; p=0.05) and dyslipidemia (0.72±0.16 mm vs 0.63±0.11 mm; p=0.029). In multivariable analysis where cardiovascular risk factor and ARV were included, IMT progression was inversely associated with CD4:CD8 ratio (OR=0.283; CI 95% 0.099–0.809; p=0.019) and treatment with NNRTI (OR=0.283; CI 95% 0.099–0.809; p=0.019). CONCLUSIONS: The inversion of CD4:CD8 ratio in treated HIV-infected patients is independently associated with IMT progression, a marker of age-associated disease. Therefore, it might be clinically useful as predictor of cardiovascular events. Surprisingly, there was a positive correlation between receiving NNRTI and progression of IMT. International AIDS Society 2014-11-02 /pmc/articles/PMC4225384/ /pubmed/25397469 http://dx.doi.org/10.7448/IAS.17.4.19723 Text en © 2014 Bernal E et al; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Sessions – Abstract P191
Bernal, Enrique
Serrano, Jose
Perez, Ana
Valero, Salvador
Garcia, Eva
Marín, Irene
Muñoz, Angeles
Miguel Gomez Verdú, Jose
Vera, Carmen
Cano, Alfredo
The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment
title The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment
title_full The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment
title_fullStr The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment
title_full_unstemmed The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment
title_short The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment
title_sort cd4:cd8 ratio is associated with imt progression in hiv-infected patients on antiretroviral treatment
topic Poster Sessions – Abstract P191
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225384/
https://www.ncbi.nlm.nih.gov/pubmed/25397469
http://dx.doi.org/10.7448/IAS.17.4.19723
work_keys_str_mv AT bernalenrique thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT serranojose thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT perezana thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT valerosalvador thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT garciaeva thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT marinirene thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT munozangeles thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT miguelgomezverdujose thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT veracarmen thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT canoalfredo thecd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT bernalenrique cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT serranojose cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT perezana cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT valerosalvador cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT garciaeva cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT marinirene cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT munozangeles cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT miguelgomezverdujose cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT veracarmen cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment
AT canoalfredo cd4cd8ratioisassociatedwithimtprogressioninhivinfectedpatientsonantiretroviraltreatment